<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05071001</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A00919-30</org_study_id>
    <nct_id>NCT05071001</nct_id>
  </id_info>
  <brief_title>Long Term Brain Toxicity of Chemotherapy in Patients Treated for a Bone TumorDuring Childhood or Adolescence</brief_title>
  <acronym>OSE</acronym>
  <official_title>Long Term Brain Toxicity of Chemotherapy in Patients Treated for a Bone TumorDuring Childhood or Adolescence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the neurocognitive outcomes in patients treated with chemotherapy for a malignant&#xD;
      bone tumor during childhood and adolescence and the factors associated with neurocognitive&#xD;
      impairment and/or complaints&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2021</start_date>
  <completion_date type="Anticipated">April 7, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 7, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>scores obtained in FactCOG as a whole and in each subscale</measure>
    <time_frame>3 years</time_frame>
    <description>Primary analysis will be performed on all patients included in the study, including history of Ewing (treated without HDMTX) and osteosarcoma (treated with HDMTX). This population is the main analysis population of the study.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">530</enrollment>
  <condition>Adults Treated During Childhood or Adolescence for a Malignant Bone Tumor (Osteosarcoma and Ewing Sarcoma)</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>This assessment will be planned in the year after the consent signAll patients will have one brain MRI performed in Henri Mondor Hospital on a 3T MR unit (Skyra, Siemens, Erlangen). The procedure will include:&#xD;
a 3D-FLAIR imaging&#xD;
a morphometric study based on a 3DT1 MPRAGE gradient echo sequence (TR / TI / TE = 2300/900 /2.9 ms)&#xD;
an analysis of the anatomic connectivity of the patient's brain assessed using a 1.5mm isotopic DTI with a high number of directions (HARDI / 65 directions / b=1500s/mm2).&#xD;
An evaluation of neuronal dysfunction using MR Spectroscopy. Spectroscopic data will be collected using a 2D CSI laser with a short TE technique.&#xD;
Magnetization transfer imaging providing information about integrity of membranes.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For study OSE A and B&#xD;
&#xD;
          -  Patients treated for a bone sarcoma: Ewing or osteosarcoma&#xD;
&#xD;
          -  Age under 19 years at initial diagnosis&#xD;
&#xD;
          -  Treated in the Pediatric Oncology Department of Gustave&#xD;
&#xD;
        For patients diagnosed between 01.01.2001 and 31.12.2010: patients alive in complete&#xD;
        remission at least 5 years after diagnosis&#xD;
&#xD;
          -  Treated with at least one course of HDMTX for osteosarcoma&#xD;
&#xD;
          -  Treated without HDMTX for Ewing sarcoma&#xD;
&#xD;
          -  Time interval between the end of treatment and inclusion &gt;10 y&#xD;
&#xD;
          -  Age &gt; 21 y at inclusion&#xD;
&#xD;
          -  Patients with informed consent signed&#xD;
&#xD;
          -  Patient under guardianship&#xD;
&#xD;
          -  Affiliated to French health insurance or beneficiary of the same or equivalent&#xD;
&#xD;
        For study OSE- B only:&#xD;
&#xD;
          -  Treated with at least 8 courses of HDMTX for osteosarcoma&#xD;
&#xD;
          -  Treated without HDMTX for Ewing sarcoma&#xD;
&#xD;
          -  Patients with Ewing sarcoma will have to be matched with osteosarcoma patients&#xD;
             according to age at the time of treatment, sex, and duration of follow-up&#xD;
&#xD;
          -  School level equivalent of at least the end of primary school&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For study OSE A and B&#xD;
&#xD;
          -  Brain radiotherapy&#xD;
&#xD;
          -  Previous relapse except those treated by local treatment without any chemotherapy&#xD;
&#xD;
          -  Second malignancy treated with chemotherapy&#xD;
&#xD;
          -  High dose chemotherapy with stem cell support&#xD;
&#xD;
          -  Non-French speaking patients&#xD;
&#xD;
          -  Pregnant and breastfeeding women&#xD;
&#xD;
        For study OSE- B only:&#xD;
&#xD;
        - Patient deprived of his liberty by a judicial or administrative decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brice Fresneau, Dr</last_name>
      <phone>01 42 11 42 47</phone>
      <email>brice.fresneau@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Lila SAIDOUN</last_name>
      <phone>01 42 11 42 11</phone>
      <phone_ext>23820</phone_ext>
      <email>Lila.saidoun@gustaveroussy.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

